Cetuximab: An epidermal growth factor receptor chimeric human-murine monoclonal antibody

Drugs of Today

Volumn 41, Issue 2, 2005, Pages 107-127

  Harding, Joanne ^a,c   Burtness, Barbara ^b  

^a PROUS SCIENCE   (Spain)

^b YALE UNIVERSITY   (United States)

^c Medical Information Department   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; NAVELBINE; PACLITAXEL; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; TRANSFORMING GROWTH FACTOR ALPHA;

ACNE; ADULT; AGED; ANAPHYLAXIS; ANEMIA; ANGIOGENESIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ASTHENIA; BACTEREMIA; CANCER INVASION; CANCER SURVIVAL; CELL CYCLE; CLINICAL TRIAL; COLORECTAL CANCER; CONJUNCTIVITIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE CALCULATION; DRUG APPROVAL; DRUG BINDING SITE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RESISTANCE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLICULITIS; GENETIC TRANSCRIPTION; HEAD AND NECK CARCINOMA; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPERSENSITIVITY REACTION; HYPOKALEMIA; HYPONATREMIA; INTERNALIZATION; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALAISE; MALE; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE DRUG DOSE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; RADIOSENSITIZATION; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; SINGLE DRUG DOSE; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; SYSTEMATIC REVIEW; THROMBOCYTOPENIA;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTINEOPLASTIC AGENTS; APOPTOSIS; AREA UNDER CURVE; CELL PROLIFERATION; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; DRUG RESISTANCE, NEOPLASM; HALF-LIFE; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RADIATION TOLERANCE; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 16244400108     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2005.41.2.882662     Document Type: Review

References (87)

1. Markowitz, S.D., Dawson, D.M., Willis, J. et al. Focus on colon cancer. Cancer Cell 2002, 1: 233.
2. Bonomi, P. Novel approaches for the treatment of non-small cell lung cancer. Semin Oncol 2001, 28(4, Suppl. 14): 45.
3. Herbst, R.S., Arquette, M.A., Nabell, L. at al. Efficacy and safety of the anti-epidermal growth factor antibody (EGFR) IMC-C225, in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy. AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Oct 29-Nov 2, Miami Beach) 2001, Abstr. 554.
4. Herbst, R.S., Shin, D.M. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors. Cancer 2002, 94: 1593.
5. De Bono, J.S., Rowinsky, E.K. The ErbB receptor family: A therapeutic target for cancer. Trends Mol Med 2002, 8 (4, Suppl.): S19.
6. Saltz, L.B. Targeting the epidermal growth factor receptor in gastrointestinal malignancies. Cancer Invest 2003, 21 (Suppl. 1): Abstr. 62.
7. Baumann, M., Krause, M. Targeting the epidermal growth factor receptor in radiotherapy: Radiobiological mechanisms, preclinical and clinical results. Radiother Oncol 2004, 72: 257-66.
8. Baselga, J. The EGFR as a target for anticancer therapy-focus on cetuximab. Eur J Cancer 2001, 37 (Suppl. 4): S16.
9. Mendelsohn, J. The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 2001, 8: 3.
10. Karashima, T., Kim, S.J., Kedar, D. et al. IMC-C225 inhibits the in vitro growth of androgen independent prostate cancer. Proc Am Assoc Cancer Res 2001, 42: Abstr. 4170.
11. Prewett, M., Overholser, J., Hooper, A. et al. Anti-EGF receptor monoclonal antibody IMC-C225 inhibits in vitro and in vivo growth of non-small cell lung carcinoma. Clin Cancer Res 2000, 6 (Suppl.): Abstr. 454.
12. Motzer, R.J., Amato, R., Todd, M. et al. Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 2003, 21: 99.
13. Ciardello, F., Bianco, R., Damiano, V. et al. Anti-angiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 2000, 6: 3739.
14. Janmaat, M.L., Kruyt, F.A., Rodriguez, J.A., Giaccone, G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: Limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 2003, 9: 2316-26.
15. Ciardiello, F., Bianco, R., Damiano, V. et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 1999, 5: 909-16.
16. Karashima, T., Sweeney, P., Slaton, J.W. et al. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice. Clin Cancer Res 2002, 8: 1253.
17. Bruns, C.J., Harbison, M.T., Davis, D.W. et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanism. Clin Cancer Res 2000, 6: 1936-48.
18. Ciardiello, F., Bianco, R., Caputo, R. et al. Antitumour activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 2004, 10: 784-93.
19. Kumar, R., Adam, L., Mandal, M. et al. Anti-invasive action of anti-EGF receptor antibody C225: Suppression of focal-adhesion kinase/B-catenin signaling components. Proc Am Assoc Cancer Res 2002, 43: Abstr. 2879.
20. Lorch, J.H., Klessner, J., Park, J.K. et al. Epidermal growth factor receptor inhibition promotes desmosome assembly and strengthens intercellular adhesion in squamous cell carcinoma cells. J Biol Chem 2004, 279: 37191-200.
21. Hadari, Y.R., Doody, J.F., Wang, Y. et al. The IgG1 monoclonal antibody cetuximab induces degradation of the epidermal growth factor receptor. Gastrointest Cancers Symp (Jan 22-24, San Francisco) 2004, Abstr. 234.
22. Arnoletti, J.P., Buchsbaum, D., Huang, Z.Q., Hawkins, A., Vickers, S. Impaired internalization of EGFR as a mechanism for resistance to erbitux (anti-EGFR Ab) combination therapy in BxPC-3 pancreatic adenocarcinoma xenografts. Gastroenterology 2004, 126 (4, Suppl. 2): Abstr. 281.
23. Prewett, M.C., Hooper, A.T., Bassi, R., Ellis, L.M., Waksal, H.W., Hicklin, D.J. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 2002, 8: 994-1003.
24. Prewett, M.C., Hooper, A.T., Bassi, R. et al. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody Erbitux (TM) (IMC-C225) in combination with irinotecan (CPT-11), 5-FU, and leucovorin against human colorectal carcinoma xenografts. Proc Am Assoc Cancer Res 2002, 43: Abstr. 2878.
25. Balin, D., Delord, J.P., Rochaix, P. et al. In vivo and in vitro enhanced antitumor activity of oxaliplatin in combination with cetuximab (C225), a chimeric monoclonal antibody anti-epidermal growth factor receptor on a panel of human colorectal tumor xenografts. Eur J Cancer 2004, 2 (8, Suppl): Abstr. 378.
26. Huang, S., Armstrong, E.A., Benavente, S., Chinnaiyan, P., Harari, P.M. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): Combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 2004, 64: 5355-62.
27. Matar, P., Rojo, F., Cassia, R. et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): Superiority over single-agent receptor targeting. Clin Cancer Res 2004, 10: 6487-501.
28. Matar, P., Rojo, R, Guzman, M. et al. Combined anti-epidermal growth factor receptor (EGFR) treatment with a tyrosine kinase inhibitor gefitinib (ZD1839, 'Iressa') and a monoclonal antibody (IMC-C225): Evidence of synergy. Proc Am Assoc Cancer Res 2003, 44 (2nd ed): Abstr. 4007.
29. Huang, S., Armstrong, E., Chinnaiyan, P. et al. Dual agent molecular targeting of the epidermal growth factor receptor: Combining anti-HER1/ EGFR monoclonal antibody with tyrosine kinase inhibitor. Proc Am Assoc Cancer Res 2003, 44 (2nd ed): Abstr. 823.
30. Jimeno, A., Oppenheimer, D., Amador, M.L., Maitra, A., Hidalgo, M. Cetuximab-induced clearance of the epidermal growth factor receptor (EGFR) overcomes resistance of cancer cells to EGFR tyrosine kinase (TK) inhibitors. Eur J Cancer 2004, 2 (8, Suppl): Abstr. 316.
31. Matar, P., Moreno-Bueno, G., Cassia, R. et al. The anti-epidermal growth factor receptor (EGFR) monoclonal antibody Cetuximab and the EGFR tyrosine kinase inhibitor Gefitinib, alone and in combination, induce a differential gene expression profile by cDNA microarray analysis in A431 cells. Proc Am Assoc Cancer Res 2004, 45: Abstr. 5335.
32. Benavente, S., Huang, S., Armstrong, E., Chi, A., Chinnaiyan, P., Harari, P.M. Establishment of acquired resistance to epidermal growth factor receptor (EGFR) inhibitors in human tumor cell lines. Proc Am Assoc Cancer Res 2004, 45: Abstr. 5333.
33. Nasu, S., Ang, K.K., Fan, Z. et al. C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. Int J Radiat Oncol Biol Phys 2001, 51: 474.
34. Helfrich, B., Raben, D., Chan, D. et al. C225 anti-epidermal growth factor receptor (EGFR) monoclonal antibody sensitizes human non-small cell lung cancer to both radiation and chemotherapy cytotoxicity in-vitro and in-vivo. Int J Radiat Oncol Biol Phys 2001, 51 (3, Suppl. 1): Abstr. 1021
35. Carpenter, M., Buchsbaum, D.M. Statistical growth curve modeling of tumors treated with Erbitux (TM) (IMC-C225) anti-EGFR antibody, gemcitabine and radiation. Proc Am Assoc Cancer Res 2002, 43: Abstr. 2386.
36. Harari, P.M., Huang, S.M. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys 2001, 49: 427.
37. Ronai, Z., Ivanov, V.N., Bhoumik, A. Role of MAPK-p38 in radiation resistance of human melanoma. Cancer Detect Prev 2000, 24 (Suppl. 1). Available in online abstract at: http//www.cancerprev.org/Journal/Issues/
38. Sun, H., Pytowski, B., Hooper, A. et al. Epidermal growth factor receptor antibody cetuximab inhibits irinotecan-induced up-regulation of mitogen-activated protein kinase phosphorylation: A possible mechanism for the enhanced effects in combination therapy of colorectal tumors. Gastrointest Cancers Symp (Jan 22-24, San Francisco) 2004, Abstr. 280.
39. Rubin, E.H., Doroshow, W., Hidalgo, M. et al. A study to assess the pharmacokinetics of a single infusion of cetuximab. Am Soc Clin Oncol Ann Meeting (June 5-8, New Orleans) 2004, Abstr. 3084.
40. Baselga, J., Pfister, D., Cooper, M.R. et al. Phase I studies of anti-epidermal growth factor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000, 18: 904.
41. Fracasso, P.M., Garrett, C., Burris, H.A. et al. A study to assess the pharmacokinetics (PK) and pharmacodynamics (PD) of a single infusion of cetuximab (IMC-C225). Proc Am Soc Clin Oncol 2003, 22: Abstr. 787.
42. Debaldo, C., Pierga, J.Y., Dieras, V. et al. Phase I pharmacokinetic [PK] evaluation of the interaction between cetuximab and irinotecan in patients with EGFR positive advanced solid tumors. Proc Am Assoc Cancer Res 2003, 44 (2nd ed): Abstr. 5353.
43. Folprecht, G., Lutz, M.P., Schoffski, P. et al. Pharmacokinetic (PK) evaluation of cetuximab in combination with weekly irinotecan (CPT-11) and 24h infusional 5FU/folinic acid (FA) as first line treatment in patients (pts) with epidermal growth factor receptor (EGFR)-positive metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2003, 22: Abstr. 890.
44. Kim, E.S., Mauer, A.M., Tran, H.T. et al. A phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer: Final report. Proc Am Soc Clin Oncol 2003, 22: Abstr. 2581.
45. Kim, E., Mauer, A., Fossella, F. et al. A phase II study of Erbitux (IMC-C225), an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer (NSCLC). Eur J Cancer 2002, 38 (Suppl. 7): S153.
46. ImClone Systems and Bristol-Myers Squibb provide Erbitux® (cetuximab) non-small cell lung cancer clinical development update. Bristol-Myers Squibb press release, October 7, 2004.
47. Van Laethem, J.L., Raoul, J.L., Mitry, E. et al. Cetuximab (C225) in combination with bi-weekly irinotecan (CPT-11), infusional 5-fluorouracil (5-FU) and folinic acid (FA) in patients (pts) with metastatic colorectal cancer (CRC) expressing the epidermal growth factor receptor (EGFR). Preliminary safety and efficacy results. Proc Am Soc Clin Oncol 2003, 22: Abstr. 1058.
48. Lutz, M.P., Schoffski, P., Folprecht, G. et al. A phase I/II study of cetuximab (C225) plus irinotecan (CPT-11) and 24h infusional 5FU/folinic acid (FA) in the treatment of metastatic colorectal cancer (MCRC) expressing the epidermal growth factor receptor (EGFR). Ann Oncol 2002, 13 (Suppl. 5): 265PD.
49. Folprecht, G., Lutz, M., Schoeffski, P. et al. Cetuximab/irinotecan/HD- FU/LV in first line therapy of metastatic colorectal cancer (CRC). Eur J Cancer 2004, 2 (8, Suppl.): Abstr. 300.
50. Cunningham, D., Humblet, Y., Siena S. et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. New Engl J Med 2004, 351: 337-45.
51. Baselga, J. EGF receptor as a target: Preclinical and clinical studies. Proc Am Assoc Cancer Res 2002, 43: Abstr.
52. Van Cutsem, E., Gascón Vilaplana, P., Seitz, J.F. et al. Cetuximab in a randomized phase II trial as a single agent or in combination with irinotecan in patients with epidermal growth factor receptor (EGFR)-expressing, irinotecan-refractory metastatic colorectal cancer (CRC). Eur J Cancer - Suppl 2003, 1 (Suppl. 5): Abstr. 1086.
53. Saltz, L., Rubin, M., Hochster, H. et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001, 20 (Part. 1): Abstr. 7.
54. Saltz, L.B., Meropol, N.J., Loehrer, P.J., Sr., Needle, M.N., Kopit, J., Mayer, R.J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004, 22: 1201-8.
55. Saltz, L.B., Meropol, N.J., Loehner Sr, P.J., Needle, M.N., Kopit, J., Mayer, R.J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004, 22: 1201.
56. Lenz, H.J., Mayer, R.J., Gold, P.J. et al. Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Am Soc Clin Oncol Ann Meeting (June 5-8, New Orleans) 2004, Abstr. 3510.
57. Hoehler, T., Dittrich, C.J., Lordick, F. et al. Aphase I/II study of cetuximab in combination with 5-fluorouracil (5-FU)/folinic acid (FA) plus weekly oxaliplatin (L-OHP) (FUFOX) in the first-line treatment of patients with metastatic colorectal cancer (mCRC) expressing epidermal growth factor receptor (EGFR). Preliminary results. Ann Oncol 2004, 15 (Suppl. 3): Abstr. 262.
58. Folprecht, G., Lutz, M., Schoeffski, P. et al. Cetuximab/irinotecan/high- dose-5-fluorouracil/leucovorin (HD-5-FU/LV) in the first-line therapy of metastatic colorectal cancer (CRC). Gastrointest Cancers Symp (Jan 22-24, San Francisco) 2004, Abstr. 283.
59. Raoul, J.L., Van Laethem, J.L., Mitry, E. et al. Phase II study of cetuximab combined with FOLFIRI (bi-weekly irinotecan plus infusional 5-FU and folinic acid (FA)) in patients (pts) with metastatic, epidermal growth factor receptor (EGFR)-expressing colorectal cancer (CRC). Eur J Cancer - Suppl 2003, 1 (Suppl. 5): Abstr. 289.
60. Rougier, P., Raoul J.L., Van Laetham, M. et al. Cetuximab + FOLFIRI as first-line treatment for metastatic colorectal CA. Proc Am Soc Clin Oncol 2004, 23: Abstr. 3513.
61. Rosenberg, A.H., Loehrer, P.J., Needle, M.N. et al. Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFr). Proc Am Soc Clin Oncol 2002, 21 (Part. 1): Abstr. 536.
62. Van Cutsem, E.J.D., Tabernero, J., Diaz-Rubin E. et al. An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing epidermal growth factor receptor (EGFR). Ann Oncol 2004, 15 (Suppl. 3): Abstr. 339P.
63. Tabernero, J.M., Van Cutsem, E., Sastre J. et al. An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing epidermal growth factor receptor (EGFR). Preliminary results. Proc Am Soc Clin Oncol 2004, 23: Abstr. 3512.
64. Badarinath, S., Mitchell, E.P., Jennis, A. et al. Cetuximab plus FOLFOX for colorectal cancer (EXPLORE): Preliminary safety analysis of a randomized phase III trial. Proc Am Soc Clin Oncol 2004, 23: Abstr. 3531.
65. Kies, M.S., Herbst, R. Epidermal growth factor receptor inhibitors in the treatment of head and neck cancer. Cancer Invest 2004, 22 (Suppl. 1): Abstr. 34.
66. Vega-Villegas, E., Awada, A., Mesia, R. et al. A phase I study of cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN). Proc Am Soc Clin Oncol 2003, 22: Abstr. 2020.
67. Humblet, Y., Vega-Villegas, E., Mesia, R. et al. Phase I study of cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc Clin Oncol 2004, 23: Abstr. 5513.
68. Shin, D.M., Donato, N.J., Perez-Soler, R. et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 2001, 7: 1204-13.
69. Kies, M.S., Arquette, M.A., Nabell, L. et al. Final report of the efficacy and safety of the anti-epidermal growth factor antibody Erbitux (IMC-C225), in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy. Proc Am Soc Clin Oncol 2002, 21 (Part. 1): Abstr. 925.
70. Hochster, H. Cetuximab (Erbitux (R), C225) antibody therapy of SCCHN, lung, and pancreatic cancer. Cancer Invest 2003, 21 (Suppl. 1): Abstr. 63.
71. Baselga, J., Trigo, J.M., Bourhis, J. et al. Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum-based regimen. Proc Am Soc Clin Oncol 2002, 21 (Part. 1): Abstr. 900.
72. Chan, A.T.C., Hsu, M.M., Goh, B.C. et al. A phase II study of cetuximab (C225) in combination with carboplatin in patients (pts) with recurrent or metastatic nasopharyngeal carcinoma (NPC) who failed to a platinum-based chemotherapy. Proc Am Soc Clin Oncol 2003, 22: Abstr. 2000.
73. Trigo, J., Hitt, R., Koralewski, P. et al. Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): Results of a phase II study. Proc Am Soc Clin Oncol 2004, 23: Abstr. 5502.
74. Robert, F., Ezekiel, M.P., Spencer, S.A. et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001, 19: 3234-43.
75. Pfister, D.G., Aliff, T.B., Kraus, D.H. et al. Concurrent cetuximab, cisplatin, and concomitant boost radiation therapy (RT) for locoregionally advanced, squamous cell head and neck cancer (SCCHN): Preliminary evaluation of a new combined-modality paradigm. Proc Am Soc Clin Oncol 2003, 22: Abstr. 1993.
76. Burtness, B.A., Li, Y., Flood, W. et al. Phase III trial comparing cisplatin (C) + placebo (P) to C + anti-epidermal growth factor antibody (EGF-R) C225 in patients (pts) with metastatic/recurrent head & neck cancer (HNC). AACR/NCI/ EORTC (Nov. 17-21, Boston) 2003, Abstr. 77.
77. Bonner, J.A., Harari, P.M., Giralt, J. et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with or without cetuximab. Am Soc Clin Oncol Ann Meeting (June 5-8, New Orleans) 2004, Abstr. 5507.
78. Bonner, J.A., Giralt, J., Harari, P.M. et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high-dose radiation therapy with or without cetuximab. 40th Annu Meet Am Soc Clin Oncol (Jun 5-8, New Orleans) 2004, Abstr. 5507
79. Giralt, J., Harari, P.M., Ang, K.K. et al. A phase III study of high-dose radiation therapy with or without cetuximab in patients with locoregionally advanced squamous cell carcinoma of the head and neck. 23rd Annu Meet Eur Soc Ther Radiol Oncol (Oct 25-28, Amsterdam) 2004, Abstr. 282.
80. Govindan, R. Cetuximab in advanced non-small cell lung cancer. Clin Can Res 2004, 10 (12, Part 2): 4241S.
81. Robert, F., Blumenschein, G., Dicke, K. et al. Phase Ib/IIa study of anti-epidermal growth factor receptor (EGFR) antibody, cetuximab, in combination with gemcitabine/carboplatin in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2003, 22: Abstr. 2587.
82. Resell, R., Daniel, C., Ramlau, R. et al. Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004, 23: Abstr. 7012.
83. Lynch, T.J., Linenbaum, R., Bonomi, P. et al. A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004, 23: Abstr. 7084.
84. Abbruzzese, J.L., Rosenberg, A.M., Lobuglio, A.F. et al. Promising survival results in a phase II study of cetuximab (IMC-C255) in combination with gemcitabine in patients with advanced pancreatic. AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Oct 29-Nov 2, Miami Beach) 2001, Abstr. 534.
85. Xiong, H.Q., Rosenberg, A., LoBuglio, A. et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: A multicenter phase II trial. J Clin Oncol 2004, 22: 2610-6.
86. Saltz, L., Kies, M., Abbruzzesse, J.L. et al. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol 2003, 22: Abstr. 817.
87. Susman, E. Rash correlates with tumour response after cetuximab. Lancet Oncol 2004, 5: 647.